Immunic Inc CEO Dr Daniel Vitt joined Proactive s Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting.
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
New assay measures molecular immune response to EBV multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
Research offers insight into future understanding of MS and its treatments medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
In MS, more severe disability is linked with complement protein activation multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.